The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-α signaling

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 13260-13270

  Le, Vu Thuy Khanh ^a   Trilling, Mirko ^a   Hengel, Hartmut ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN UL138; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA SEQUENCE; GENE DELETION; GENE TARGETING; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UL138 GENE; ULB GENE; UPREGULATION; VIRUS GENE; VIRUS GENOME;

CELL LINE; CYTOMEGALOVIRUS; GENE DELETION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOPRECIPITATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 5;

EID: 84855296602     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06005-11     Document Type: Article

References (71)

1. Atalay, R., et al. 2002. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fc gamma receptor homologs. J. Virol. 76:8596-8608.
2. Baillie, J., D. A. Sahlender, and J. H. Sinclair. 2003. Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J. Virol. 77:7007-7016.
3. Bego, M., J. Maciejewski, S. Khaiboullina, G. Pari, and S. St. Jeor. 2005. Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J. Virol. 79:11022-11034.
4. Benedict, C. A., et al. 2001. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor- 1 and -2. J. Biol. Chem. 276:3270-3278.
5. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
6. Bradley, A. J., et al. 2009. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J. Gen. Virol. 90:2375-2380.
7. Burgert, H. G., et al. 2002. Subversion of host defense mechanisms by adenoviruses. Viral Proteins Counteract. Host Defenses 269:273-318.
8. Cha, T. A., et al. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:78-83.
9. Chen, G. Q., and D. V. Goeddel. 2002. TNF-R1 signaling: a beautiful pathway. Science 296:1634-1635.
10. Chen, P., J. Tian, I. Kovesdi, and J. T. Bruder. 1998. Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J. Biol. Chem. 273:5815-5820.
11. Chin, Y. R., and M. S. Horwitz. 2005. Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex. J. Virol. 79:13606-13617.
12. Chin, Y. R., and M. S. Horwitz. 2006. Adenovirus RID complex enhances degradation of internalized tumour necrosis factor receptor 1 without affecting its rate of endocytosis. J. Gen. Virol. 87:3161-3167.
13. Davison, A. J., et al. 2009. The order Herpesvirales. Arch. Virol. 154:171-177.
14. DeMeritt, I. B., L. E. Milford, and A. D. Yurochko. 2004. Activation of the NF-kappa B pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J. Virol. 78:4498-4507.
15. Dolan, A., et al. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85:1301-1312.
16. Fessler, S. P., Y. R. Chin, and M. S. Horwitz. 2004. Inhibition of tumor necrosis factor (TNF) signal transduction by the adenovirus group C RID complex involves downregulation of surface levels of TNF receptor 1. J. Virol. 78:13113-13121.
17. Fietze, E., et al. 1994. Cytomegalovirus infection in transplant recipients-the role of tumor necrosis factor. Transplantation 58:675-680.
18. Fishman, J. A., and R. H. Rubin. 1998. Infection in organ-transplant recipients. N. Engl. J. Med. 338:1741-1751.
19. Gooding, L. R., et al. 1991. The 10,400-Dalton and 14,500-Dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse-cell lines against lysis by tumor necrosis factor. J. Virol. 65:4114-4123.
20. Gooding, L. R., I. O. Sofola, A. E. Tollefson, P. Duerksenhughes, and W. S. M. Wold. 1990. The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis. J. Immunol. 145:3080-3086.
21. Goodrum, F., M. Reeves, J. Sinclair, K. High, and T. Shenk. 2007. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937-945.
22. Grainger, L., et al. 2010. Stress-inducible alternative translation initiation of human cytomegalovirus latency protein pUL138. J. Virol. 84:9472-9486.
23. Grivennikov, S. I., D. V. Kuprash, Z. G. Liu, and S. A. Nedospasov. 2006. Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int. Rev. Cytol. 252:129-161.
24. Hahn, G., et al. 2002. The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J. Virol. 76:9551-9555.
25. Hahn, G., et al. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78:10023-10033.
26. Hargett, D., and T. E. Shenk. 2010. Experimental human cytomegalovirus latency in CD14(+) monocytes. Proc. Natl. Acad. Sci. U. S. A. 107:20039-20044.
27. Hengel, H., C. Esslinger, J. Pool, E. Goulmy, and U. H. Koszinowski. 1995. Cytokines restore MHC class-I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J. Gen. Virol. 76:2987-2997.
28. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
29. Hummel, M., et al. 2001. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J. Virol. 75:4814-4822.
30. Ito, M., and J. A. Omalley. 1987. Antiviral effects of recombinant human tumor necrosis factor. Lymphokine Res. 6:309-318.
31. Jarvis, M. A., et al. 2006. Human cytomegalovirus attenuates interleukin-1 beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappa B activation. J. Virol. 80:5588-5598.
32. Jenkins, C., A. Abendroth, and B. Slobedman. 2004. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J. Virol. 78:1440-1447.
33. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-kappa B activity. Annu. Rev. Immunol. 18:621-663.
34. Kim, H. J., and M. P. Foster. 2002. Characterization of Ad5 E3-14.7K, an adenoviral inhibitor of apoptosis: structure, oligomeric state, and metal binding. Protein Sci. 11:1117-1128.
35. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631-664.
36. Kutza, A. S. T., E. Muhl, H. Hackstein, A. Kirchner, and G. Bein. 1998. High incidence of active cytomegalovirus infection among septic patients. Clin. Infect. Dis. 26:1076-1082.
37. Lavrik, I., A. Golks, and P. H. Krammer. 2005. Death receptor signaling. J. Cell Sci. 118:265-267.
38. Le, V. T. K., M. Trilling, M. Wilborn, H. Hengel, and A. Zimmermann. 2008. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol. 89:2416-2426.
39. Li, Y. G., et al. 1999. Identification of a cell protein (FIP-3) as a modulator of NF-kappa B activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 96:1042-1047.
40. Lichtenstein, D. L., K. Toth, K. Doronin, A. E. Tollefson, and W. S. M. Wold. 2004. Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 23:75-111.
41. Liou, H. C. 2002. Regulation of the immune system by NF-kappa B and I kappa B. J. Biochem. Mol. Biol. 35:537-546.
42. Lucin, P., et al. 1994. Late-phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumor necrosis factor. J. Gen. Virol. 75:101-110.
43. MacEwan, D. J. 2002. TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal. 14:477-492.
44. Mohamed, M. R., and G. McFadden. 2009. NF kappa B inhibitors strategies from poxviruses. Cell Cycle 8:3125-3132.
45. Montag, C., J. Wagner, I. Gruska, and C. Hagemeier. 2006. Human cytomegalovirus blocks tumor necrosis factor alpha- and interleukin-1 betamediated NF-kappa B signaling. J. Virol. 80:11686-11698.
46. Murphy, E., et al. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 100:14976-14981.
47. Mutimer, D., D. Mirza, J. Shaw, K. O'Donnell, and E. Elias. 1997. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 63:1411-1415.
48. Petrucelli, A., M. Rak, L. Grainger, and F. Goodrum. 2009. Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. J. Virol. 83:5615-5629.
49. Poole, E., C. A. King, J. H. Sinclair, and A. Alcami. 2006. The UL144 gene product of human cytomegalovirus activates NF kappa B via a TRAF6-dependent mechanism. EMBO J. 25:4390-4399.
50. Popkin, D. L., and H. W. Virgin. 2003. Murine cytomegalovirus infection inhibits tumor necrosis factor alpha responses in primary macrophages. J. Virol. 77:10125-10130.
51. Powers, C., V. DeFilippis, D. Malouli, and K. Fruh. 2008. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 325:333-359.
52. Prösch, S., et al. 1995. Stimulation of the human cytomegalovirus IE enhancer promoter in HL-60 cells by TNF-alpha is mediated via induction of NF-kappa-B. Virology 208:197-206.
53. Prösch, S., et al. 2000. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 272:357-365.
54. Qi, Y., et al. 2009. Human cytomegalovirus UL138 open reading frame is highly conserved in clinical strains. Chin. Med. Sci. J. 24:107-111.
55. Reeves, M. B., P. A. Macary, P. J. Lehner, J. G. P. Sissons, and J. H. Sinclair. 2005. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl. Acad. Sci. U. S. A. 102:4140-4145.
56. Schneider-Brachert, W., et al. 2006. Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J. Clin. Investig. 116:2901-2913.
57. Shisler, J., C. Yang, B. Walter, C. F. Ware, and L. R. Gooding. 1997. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to fas-induced apoptosis. J. Virol. 71:8299-8306.
58. Simon, C. O., C. K. Seckert, D. Dreis, M. J. Reddehase, and N. K. A. Grzimek. 2005. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J. Virol. 79:326-340.
59. Sinzger, C., et al. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89:359-368.
60. Sinzger, C., et al. 1999. Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J. Gen. Virol. 80:2867-2877.
61. Söderberg-Nauclér, C., K. N. Fish, and J. A. Nelson. 1997. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119-126.
62. Stewart, A. R., A. E. Tollefson, P. Krajcsi, S. P. Yei, and W. S. M. Wold. 1995. The adenovirus E3 10.4K and 14.5K proteins, which function to prevent cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane. J. Virol. 69:172-181.
63. Taylor, R. T., and W. A. Bresnahan. 2006. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor alpha-induced NFKB-dependent gene expression. J. Virol. 80:10763-10771.
64. Tollefson, A. E., et al. 1998. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392:726-730.
65. Tollefson, A. E., et al. 2001. Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J. Virol. 75:8875-8887.
66. Trilling, M., et al. 2009. Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. J. Virol. 83:3684-3695.
67. Van Herreweghe, F., N. Festjens, W. Declercq, and P. Vandenabeele. 2010. Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell. Mol. Life Sci. 67:1567-1579.
68. Wagner, M., A. Gutermann, J. Podlech, M. J. Reddehase, and U. H. Koszinowski. 2002. Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J. Exp. Med. 196:805-816.
69. Wajant, H., K. Pfizenmaier, and P. Scheurich. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10:45-65.
70. White, E. 1998. Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin. Virol. 8:505-513.
71. Yurochko, A. D., T. F. Kowalik, S. M. Huong, and E. S. Huang. 1995. Human cytomegalovirus up-regulates NF-kappa-B activity by transactivating the NFkappa-B P105/P50 and P65 promoters. J. Virol. 69:5391-5400.